Establishment Labs (ESTA) Stock Slides After Q3 Earnings Turn Cash Positive

Establishment Labs Holdings just watched its stock slide 8.8% to about US$62 in the first trading session after reporting Q3 2026. The initial reaction is harsh. Yet the headline from the quarter is not collapse. It is a cosmetic implants specialist putting up roughly US$72 million in sales and, for the first time, generating positive free cash flow of US$5.1 million.

Short-term traders see a falling share price. Long-term holders are staring at a business that is still loss making on a GAAP basis but now generating cash and lifting full year revenue guidance.

Love the first taste of free cash flow at Establishment Labs Holdings but concerned that GAAP losses still hang over the story? Check out our list of cash generative growth stocks in the list of solid balance sheet and fundamentals stocks (25 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): US$71.99 million vs. US$53.78 million (up about 33.9%)
• Net Loss (Q3 2026 vs Q3 2025): loss of US$10.71 million vs. loss of US$11.15 million (narrowed modestly)
• Basic EPS (Q3 2026 vs Q3 2025): loss of US$0.35 per share vs. loss of US$0.38 per share (slightly improved)
• Free Cash Flow (Q3 2026 vs Q3 2025): positive US$5.1 million vs. negative free cash flow a year ago (first quarter of positive free cash generation)

U.S. sales more than doubled and drove a guidance raise. Ask Charlie what made Establishment Labs’ U.S. growth explode.

Establishment Labs bullish mix shift under scrutiny

Bulls frame Establishment Labs as a higher value procedure engine, not just a volume story.

"Preservé procedures that allow surgeons to charge 30 to 50% more than traditional augmentation, and more than a 2x procedural premium in the U.S., create room for Establishment Labs Holdings to tilt the mix toward higher ticket minimally invasive cases that support structurally higher gross margins and potentially stronger net margins."

Q3 gives real evidence. Minimally invasive revenue reached about US$9 million and roughly 15% of year to date sales, with Preservé about 17% of U.S. turnover. Adjusted gross margin of 70.8% and the first quarter of positive free cash flow indicate the mix is starting to work, even with distributor heavy OUS revenue diluting margin optics.

Bear case tests U.S. adoption and margin resilience

Skeptics worry that U.S. uptake and margin ambition baked into the story could prove too optimistic.

"The main thing that has to go right is continued rapid U.S. and direct-market adoption of Motiva and the minimally invasive platform, so that higher-margin procedures and operating leverage keep translating into sustained gross margins above 70% and positive adjusted EBITDA."

Current numbers argue partly against that fear. U.S. sales of US$26 million grew much faster than OUS regions and now contribute about 36% of total revenue. Minimally invasive turnover more than doubled, and adjusted EBITDA reached US$6.4 million with adjusted gross margin just above 70%. The share price fall of about 9% suggests investors still question how repeatable these milestones are.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Hunt For Quiet Pricing Dislocations

Establishment Labs Holdings just reminded investors that a stronger quarter and a weaker share price can appear together. The real opportunity is spotting stocks that could be undervalued before the gap closes.

• Company 1 - 38% below our estimate - extend a new production buildout while leaning harder into higher margin films, services and dealer channels.
• Company 2 - 46% below our estimate - expand a solar hardware platform by scaling newer storage, inverter and non tracker products to deepen customer reliance on its control software.
• Company 3 - 29% below our estimate - compound a rapidly expanding digital banking base by lifting revenue per active user while holding efficiency ratios below incumbents.

Three companies from the same screener. Open all 29 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com